ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

HHS System Of Misconduct investigation Not Suited For Clinical Trials, Broder Says

November 11, 1994

Ethics Commission To Take Up Again Compensation Issue

September 11, 1981

Otis Brawley To Succeed Harmon Eyre As American Cancer Society’s Chief Medical Officer.

August 3, 2007

Mammography Controversy Continues: Task Force Alters Web Site To Clarify Recommendation On Mammography

December 4, 2009

Cancer Death Rate Declines, Clark Tells Science Writers

April 8, 1977

Patients Prefer Silicone Over Saline Implants

November 26, 2010